Finanzen von Filana Therapeutics Inc (FLNA)FLNAFilana Therapeutics Inc

Evaluating the bottom line, Filana Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -55.78%, provide a clear picture of how effectively FLNA converts its operational activities into shareholder value.

In the context of the broader market, FLNA competes directly with industry leaders such as PMN and IXHL. With a market capitalization of $21.64M, it holds a significant position in the sector. When comparing efficiency, FLNA's gross margin of N/A stands against PMN's N/A and IXHL's N/A. Such benchmarking helps identify whether Filana Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Filana Therapeutics has reported consistent net losses, with a net income of -$44,224,000 in Q2 2025 and a gross profit of $0 for multiple quarters, indicating significant financial distress. The company has a current ratio of 2.08, suggesting it can cover its short-term liabilities, but its negative earnings and cash burn are concerning.